Predictive Oncology Files 8-K
Ticker: AGPU · Form: 8-K · Filed: Sep 29, 2025 · CIK: 1446159
Sentiment: neutral
Topics: 8-K, reporting, financials
Related Tickers: POAI
TL;DR
Predictive Oncology (POAI) filed an 8-K on 9/29/25. Standard reporting.
AI Summary
Predictive Oncology Inc. filed an 8-K on September 29, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Skyline Medical Inc., is incorporated in Delaware and headquartered in Pittsburgh, PA.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and exhibits, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This is a standard 8-K filing for reporting purposes, not indicating any immediate material adverse events.
Key Numbers
- 001-36790 — SEC File Number (Identifies the company's filing with the SEC.)
- 33-1007393 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Predictive Oncology Inc. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- Skyline Medical Inc. (company) — Former company name
- Delaware (jurisdiction) — State of Incorporation
- Pittsburgh, PA (location) — Business Address City and State
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report under Regulation FD and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on September 29, 2025.
What were some of the former names of Predictive Oncology Inc.?
Predictive Oncology Inc. was formerly known as Skyline Medical Inc., Precision Therapeutic Inc., and Precision Therapeutics Inc.
In which state is Predictive Oncology Inc. incorporated?
Predictive Oncology Inc. is incorporated in Delaware.
What is the business address of Predictive Oncology Inc.?
The business address is 91 43rd Street, Suite 110, Pittsburgh, PA 15201.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-09-29 09:47:54
Key Financial Figures
- $0.01 — ange on which registered Common stock, $0.01 par value POAI Nasdaq Capital Market
Filing Documents
- f8k_092925.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 14KB
- 0001171843-25-006119.txt ( ) — 228KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_092925_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On September 29, 2025, Predictive Oncology Inc. (the "Company") issued a press release announcing two private placements and its adoption of a digital asset treasury strategy. The Company intends to continue to pursue its current lines of business in addition to the pursuit of its digital asset treasury strategy. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibits 99.1 Press Release dated September 29, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Predictive Oncology Inc. Date: September 29, 2025 By: /s/ Josh Blacher Josh Blacher Interim Chief Financial Officer